Healthcare · Biotechnology
Price
$3.73
Market Cap
$64.5M
Employees
2
Beta
2.19
Avg Volume
1,264,767
CEO
Jonathan C. Javitt
Business Description
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, a pair of oral therapeutics designed to address bipolar depression, specifically in patients exhibiting acute or sub-acute suicidal thoughts and behaviors. Established in 2015, NRx Pharmaceuticals is headquartered in Wilmington, Delaware.
Business History
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-2.78
Stock Price: $3.73
EPS (Diluted): -1.34
EPS (Diluted): -1.34
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
-3.64
Stock Price: $3.73
Total Equity: -$15.94M
Shares: 21,401,683
Total Equity: -$15.94M
Shares: 21,401,683
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-2.52
Market Cap: $64.48M
Total Debt: $0.00
Cash: $7.80M
EBITDA: -$27.81M
Total Debt: $0.00
Cash: $7.80M
EBITDA: -$27.81M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$50.8M
Market Cap: $64.48M
Total Debt: $0.00
Cash: $7.80M
Total Debt: $0.00
Cash: $7.80M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
47.35
Stock Price: $3.73
Revenue: $1.23M
Shares: 21,401,683
Revenue: $1.23M
Shares: 21,401,683
EV/Sales (Total value vs revenue — works when P/E can't)
API41.50
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
58.8%
Gross Profit: $720,000
Revenue: $1.23M
Revenue: $1.23M
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
-1,324.4%
Operating Income: -$16.22M
Revenue: $1.23M
Revenue: $1.23M
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
-2,336.5%
Net Income: -$28.62M
Revenue: $1.23M
Revenue: $1.23M
ROE (Profit from shareholder equity)
APINet Income / Total Equity
107.7%
Net Income: -$28.62M
Total Equity: -$15.94M
Total Equity: -$15.94M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
133.4%
Operating Income: -$16.22M
Tax Rate: 0.0%
Equity: -$15.94M
Total Debt: $0.00
Cash: $7.80M
Tax Rate: 0.0%
Equity: -$15.94M
Total Debt: $0.00
Cash: $7.80M
Zero debt — invested capital = equity minus cash (very efficient)
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
0.31
Current Assets: $8.89M
Current Liabilities: $28.58M
Current Liabilities: $28.58M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.00
Short-Term Debt: $0.00
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: -$15.94M
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: -$15.94M
Zero debt — this company carries no debt obligations. Strongest possible score.
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$0.06
Revenue: $1.23M
Shares: 21,401,683
Shares: 21,401,683
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$-0.74
Total Equity: -$15.94M
Shares: 21,401,683
Shares: 21,401,683
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-0.66
Operating CF: -$14.11M
CapEx: $0.00
Shares: 21,401,683
CapEx: $0.00
Shares: 21,401,683
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $3.73
Stock Price: $3.73
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$28.62M
Net Income: -$28.62M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares NRXP against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 23, 2026 3:11pm (3d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $1.2M |
| Cost of Revenue | $2,000 | $4,000 | $5,000 | $5,000 | $505,000 |
| Gross Profit | $-2,000 | $-4,000 | $-5,000 | $-5,000 | $720,000 |
| Operating Expenses | $95.2M | $44.3M | $27.6M | $19.7M | $16.9M |
| Operating Income | -$95.2M | -$44.3M | -$27.6M | -$19.7M | -$16.2M |
| Net Income | -$93.1M | -$39.8M | -$30.2M | -$25.1M | -$28.6M |
| EBITDA | -$93.0M | -$39.8M | -$30.0M | -$24.0M | -$27.8M |
| EPS | $-7.44 | $-0.60 | $-3.98 | $-2.39 | $-1.34 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 23, 2026 3:11pm (3d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $27.6M | $20.1M | $4.6M | $1.4M | $7.8M |
| Total Current Assets | $32.7M | $25.8M | $6.9M | $3.3M | $8.9M |
| Total Assets | $32.7M | $25.8M | $7.3M | $3.7M | $13.0M |
| Current Liabilities | $11.9M | $15.6M | $19.0M | $21.9M | $28.6M |
| Long-Term Debt | $0 | $2.8M | $0 | $5.0M | $0 |
| Total Liabilities | $11.9M | $18.4M | $19.0M | $26.9M | $28.9M |
| Total Equity | $20.8M | $7.4M | -$11.7M | -$23.2M | -$15.9M |
| Retained Earnings | -$183.2M | -$223.0M | -$253.1M | -$278.3M | -$306.9M |
Cash Flow (Annual)
Last updated: Jun 23, 2026 3:11pm (3d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$37.7M | -$39.8M | -$21.7M | -$10.6M | -$14.1M |
| Capital Expenditure | $-7,000 | $-10,000 | $-3,000 | $0 | $0 |
| Free Cash Flow | -$37.7M | -$39.8M | -$21.7M | -$10.6M | -$14.1M |
| Acquisitions (net) | $0 | $0 | $0 | $0 | -$2.4M |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $25.7M | -$7.6M | -$15.5M | -$3.2M | $6.4M |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 6:39am (2h ago)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$165.6M $68.3M – $262.9M
|
$498.8M $155.9M – $1.0B
|
$745.1M $232.9M – $1.5B
|
$935.1M $292.2M – $1.9B
|
| EBITDA |
$99.4M $41.0M – $157.7M
|
$299.3M $93.5M – $601.3M
|
$447.1M $139.7M – $898.3M
|
$561.0M $175.3M – $1.1B
|
| Net Income |
$7.5M $6.4M – $8.6M
|
$64.4M $5.7M – $123.2M
|
$96.5M $10.3M – $223.2M
|
$123.3M $13.1M – $285.0M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 23, 2026 3:11pm (3d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | — | — | — | — |
| Gross Profit Growth | -100.0% | -25.0% | +0.0% | +14,500.0% |
| Operating Income Growth | +53.4% | +37.8% | +28.6% | +17.7% |
| Net Income Growth | +57.3% | +24.2% | +16.7% | -13.9% |
| EBITDA Growth | +57.3% | +24.5% | +19.9% | -15.7% |
Insider Trading (Recent)
Last updated: Jun 27, 2026 6:39am (2h ago)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-01-27 | Casper Joseph Michael | A-Award | 100,000.00 | $2.39 | $239,000 |
| 2026-01-27 | Casper Joseph Michael | 100,000.00 | $2.39 | $239,000 | |
| 2025-04-09 | Javitt Jonathan C | A-Award | 125,000.00 | $1.73 | $216,213 |
| 2025-04-09 | McBride Dennis | A-Award | 25,000.00 | $1.73 | $43,243 |
| 2025-04-09 | Hurvitz Chaim | A-Award | 25,000.00 | $1.73 | $43,243 |
| 2025-04-09 | Flynn Patrick John | A-Award | 50,000.00 | $1.73 | $86,485 |
| 2025-08-18 | B Group, Inc. | 0.00 | $0.00 | $0 | |
| 2025-02-07 | ABRAMS MICHAEL S | A-Award | 50,000.00 | $2.94 | $147,000 |
| 2024-12-17 | Javitt Jonathan C | P-Purchase | 40,000.00 | $1.17 | $46,800 |
| 2024-11-18 | ABRAMS MICHAEL S | 0.00 | $0.00 | $0 | |
| 2024-06-13 | McBride Dennis | 6,320.00 | $15.30 | $96,696 | |
| 2023-12-28 | Rehnquist Janet | 0.00 | $0.00 | $0 | |
| 2023-09-13 | Narido Richard Clavano | 0.00 | $0.00 | $0 | |
| 2023-08-30 | Gorovitz Aaron | P-Purchase | 35,000.00 | $0.32 | $11,197 |
| 2023-08-30 | Hurvitz Chaim | P-Purchase | 70,000.00 | $0.29 | $20,125 |
| 2023-08-23 | Javitt Jonathan C | P-Purchase | 100,000.00 | $0.33 | $33,000 |
| 2023-08-22 | Javitt Jonathan C | P-Purchase | 200,000.00 | $0.32 | $64,400 |
| 2022-12-31 | Javitt Jonathan C | 0.00 | $0.00 | $0 | |
| 2022-12-16 | Willard Stephen H | P-Purchase | 50,000.00 | $1.17 | $58,500 |
| 2022-12-16 | VAN VOORHEES SETH | P-Purchase | 30,000.00 | $1.10 | $33,000 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for NRXP — it's generated by the pipeline (
market-narrative step).
No community reviews yet for NRXP.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30